Developer of psilocybin to treat neuroinflammatory conditions Nova Mentis Life Science Corp. (CNSX) (OTCQB: NMLSF) says that it’s currently building a serotonin research center in Winter Garden, Florida.
Nova Mentis is carrying out this project in collaboration with FourthWall Testing. The company says the neuroinflammatory research program is aimed at identifying biomarkers which can be used to test the therapeutic efficacy of its main psilocybin-based drug portfolio.
Not long ago, Nova Mentis said its psilocybin drug has the ability to modulate anxiety-like behaviour in a valproic acid (VPA) rat autism model. This test was conducted in partnership with the laboratory of Dr. Viviana Trezza, Roma Tre University, Rome, Italy.
The company is looking forward to unveiling a longitudinal data bank to help in inner studies of the microbiome and its relationship to serotonin activity and behavioral metrics as they relate to autism spectrum disorder (ASD).
The study will begin with an observational study of individuals diagnosed with ASD and fragile X syndrome (FXS).
